Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Schering-Plough, Shionogi to Comarket Antiallergic Claritin
January 29, 2001
- Phase III Comparative Study on Progressive Lung Cancer Begins
January 29, 2001
- Toho Ties Up with Tsuruhara Yoshii in Kumamoto
January 29, 2001
- Overall Mortality Increases at Total Cholesterol of 180 mg/dl or Less
January 29, 2001
- Santen Agrees with Nippon Organon to Develop, Manufacture, Market Glaucoma Treatment
January 29, 2001
- Novartis 5-Generation Campaign Recruits 378 Families
January 29, 2001
- Sankyo Completes Purchase of Sankyo Parke Davis Stocks from Pfizer
January 29, 2001
- WHO GLs for Allergic Rhinitis Introduced at UCB Symposium
January 29, 2001
- Kuraya Sanseido Aims at Sales of \1.5 Trillion in Next Stage
January 29, 2001
- BI Establishes Virtual Research Institute of Aging
January 29, 2001
- EMA Dissatisfied with FPMAJ Policy Regarding Healthcare Reform
January 29, 2001
- GlaxoSmithKline Opens Call-Centre for Health Professionals, Patients
January 22, 2001
- 16 Ingredients to Be Added to Orange Book
January 22, 2001
- PDA International Congress to Be Held from Feb. 19 to 21
January 22, 2001
- Company Leaders Stress Importance of Globalization, IT Revolution
January 22, 2001
- REGULATORY NEWS IN BRIEF -1-
January 22, 2001
- Fujisawa to Reorganize European Operations
January 22, 2001
- Drug Industry Should Earn More Foreign Currency: Mr Fujiyama of FPMAJ
January 22, 2001
- REGULATORY NEWS IN BRIEF -2-
January 22, 2001
- FJPWA Opposes Harsher Changes in NHI Price Revision Rule: Mr Kojima
January 22, 2001
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…